Podcasts about Atopic dermatitis

A young woman is on a mission to shed light on the harsh realities of living with Atopic Dermatitis. 19-year-old Alicja Stachurska from Lisdoonvarna, has launched an online awareness campaign through Instagram after years of struggling with the debilitating skin condition, also known as eczema. From sleepless nights to a visit to the A&E, Alicja says she reached a breaking point — and decided to take action. Her page, malinka_eczema, shares personal updates, practical advice, and candid reflections with the goal of supporting others in similar situations. Clare FM's Ewelina Szybinska caught up with Alicja to hear more about her journey — and why she believes raw honesty is key to healing... Check out Alicja's instagram here: https://www.instagram.com/malinka_eczema/ Photo(C): Alicja Stachurska

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

Listen in as Evette Whaley and Katie Smiley PA-C talk about innovative strategies for NPs and PAs to improve treatment for pediatric patients with atopic dermatitis. They discuss how to assess the whole patient and their family to better understand the impact of the disease on their quality of life. They also discuss newer treatments and how they can be incorporated into a comprehensive management plan for pediatric patients and their caregivers. Presenters:Evette WhaleyCaregiverBaltimore, Maryland Katie Smiley PA-CGrants & Clinical DirectorProgram Coordinator, Multidisciplinary Atopic Dermatitis ProgramAllergy & Asthma Medical GroupRady Children's HospitalSan Diego, CaliforniaLink to full program:https://bit.ly/43svVyJ

Dr. Mohannad Abu-Hilal is a dermatologist and assistant professor in the department of medicine at McMaster University in Hamilton.

(Airdate 4/18/25) Paul Wallace, MD, MPA, is a celebrity cosmetic dermatologist providing medical dermatology services in Ladera Heights at Wallace Skin & Body Institute. For over 20 years, he has offered natural and alternative approaches to dermatological problems, including acne and eczema, to help his patients look and feel their best. After earning his undergraduate degree with honors from UC Berkeley, Dr. Wallace went on to Harvard Medical School, earned a master's in Public Administration from the University of Missouri, and studied urban and rural medicine at Oklahoma University.https://www.wallaceskinandbodyinstitute.com/https://www.dominiquediprima.com/

(Airdate 4/18/25) Paul Wallace, MD, MPA, is a celebrity cosmetic dermatologist providing medical dermatology services in Ladera Heights at Wallace Skin & Body Institute. For over 20 years, he has offered natural and alternative approaches to dermatological problems, including acne and eczema, to help his patients look and feel their best. After earning his undergraduate degree with honors from UC Berkeley, Dr. Wallace went on to Harvard Medical School, earned a master's in Public Administration from the University of Missouri, and studied urban and rural medicine at Oklahoma University.https://www.wallaceskinandbodyinstitute.com/https://www.dominiquediprima.com/

With all these novel treatments for psoriasis and eczema available, how can your patients choose? Don't worry, we've got a plan. This week, we're joined by Dr. Peter Lio as he introduces ESTAR, a system to help patients choose medications. Listen in as he discusses a new paradigm to empower your patients and make choosing treatments a collaborative process. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Hear Dr. Lio live at IDS 2025 for a deep dive with fellow experts during the “Integrative Approach to Eczema” panel. View Agenda: https://bit.ly/42joj2r   Peter Lio, MD is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University. He received his medical degree from Harvard Medical School and his Dermatology training at Harvard. While at Harvard, he received formal training in acupuncture. Dr. Lio is the founding director of the Chicago Integrative Eczema Center and a founding faculty member of the Integrative Dermatology Certificate Program with over 400 publications and 4 textbooks.    

Diego Dasilva, MD, FAAD interviewed by Deirdre Hooper, MD, FAAD

This week's episode is a replay! We ran into some technical difficulties with a guest episode that was scheduled for this week (super excited about this guest) and will release at a later date. Stay tuned!So... you have ruled out flea and food allergy and now it is time for THE talk. The chronic, lifelong, multimodal therapy required atopic dermatitis talk? For such a common disease, how come this spiel can be so difficult? Check out this week's episode of The Derm Vet podcast for tips and tricks!TIMESTAMPSIntro 00:00Explaining Feline Atopic Skin Syndrome To Pet Owners 00:56The Reasoning For Atopic Dermatitis In Pets 05:04Explaining Multimodal Therapy To Pet Owners 11:08Outro 14:02

In this episode of Derms and Conditions, Dr James Q. Del Rosso welcomes back his longtime friend and pediatric dermatology expert, Dr Lisa Swanson. Together, they explore the rapidly evolving treatment landscape for pediatric atopic dermatitis, with a focus on newly approved non-steroidal topical therapies. Dr Swanson shares her insights on tapinarof 1% cream, now FDA-approved for patients as young as two years old, and topical roflumilast 0.15% cream, approved down to age six. The duo discusses how aryl hydrocarbon receptor (AhR) agonism makes tapinarof effective in both atopic dermatitis and psoriasis, likening its action to a “SNOO” that adjusts to soothe inflammation. They also dive into data from the ADORING 1 and ADORING 2 phase 3 trials, highlighting tapinarof's rapid reduction in itch and its positive impact on sleep—critical outcomes for both children and their parents. Dr Swanson offers real-world anecdotes about the sleep-depriving toll of pediatric eczema and how effective therapies can restore rest for the entire family. The conversation touches on skin of color considerations, including how atopic dermatitis may present differently and why diverse representation in clinical trials is essential. Dr Swanson underscores the importance of tactile assessments and shares practical pearls for evaluating eczema severity across skin types. Finally, they explore safety and tolerability, emphasizing tapinarof's low risk of systemic absorption, even in young children prone to thumb-sucking or hand-to-mouth behavior. Tune in for clinical pearls, new treatment insights, and a few laughs between two dermatology BFFs.

Guest: Katrina Abuabara, MD, FAAD Phototherapy, biologics, and JAK inhibitors can all play a role in atopic dermatitis treatment, but it's essential to consider patient-specific factors before choosing one of these options. Dr. Katrina Abuabara, Associate Professor of Dermatology at the University of California, San Francisco School of Medicine, explains how we should approach these decisions when caring for patients with atopic dermatitis. Dr. Abuabara also spoke on this topic at the 2025 American Academy of Dermatology Annual Meeting.

Guest: Katrina Abuabara, MD, FAAD Phototherapy, biologics, and JAK inhibitors can all play a role in atopic dermatitis treatment, but it's essential to consider patient-specific factors before choosing one of these options. Dr. Katrina Abuabara, Associate Professor of Dermatology at the University of California, San Francisco School of Medicine, explains how we should approach these decisions when caring for patients with atopic dermatitis. Dr. Abuabara also spoke on this topic at the 2025 American Academy of Dermatology Annual Meeting.

Join Dr. Renda Knapp, a board-certified OB/GYN, and Dr. Rachel Schultz, a pediatric specialist, as they tackle one of the most common skin conditions affecting infants: eczema (atopic dermatitis). In this informative podcast, our medical experts explain everything parents need to know about managing their baby's sensitive skin. This podcast offers practical guidance for daily management and long-term care. Whether you're a new parent noticing your baby's first patches of dry, irritated skin or looking for better ways to manage your child's established eczema, this podcast delivers compassionate, evidence-based advice to help your little one find relief. Subscribe for weekly episodes.

Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

Teresa Wright, MD, FAAD, FAAP, joins host Dr. Edith Bracho-Sanchez to talk about eczema or atopic dermatitis, a common skin condition that causes dry, red, itchy rashes. They look at causes, treatments, tips to prevent flare-ups and whether the condition will improve as children get older.  

What's new in dermatology? DEF Advisory Council Members address some of the latest approvals and therapeutic updates of the past year. Hear from Joe Gorelick, MSN, FNP-C; Andrea Nguyen, DMSc, MPAS, PA-C; Kara Gooding, MMS, PA-C; and Alexa Hetzel, MS, PA-C, as they address new developments in atopic dermatitis, psoriasis, and hidradenitis suppurativa. Plus, winter skin care tips and a fresh take on JAK inhibitors from Brad Glick, DO, FAAD.Like what you're hearing? Want to learn more about the Dermatology Education Foundation? Explore assets and resources on our website.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Suhua Jiang from the Department of Paediatrics, The First People's Hospital of Foshan, Foshan, People's Republic of China and Professor Lin Zhang, Assistant Professor from Department of Anaesthesia and Intensive Care and Lead Scientist, Microbiota I-Center (MagIC) in the Chinese University of Hong Kong, on the paper "Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis" published in paper copy in Gut in January 2025.   A close transcript of this podcast is available at this link: https://bit.ly/40jF5xo    Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/recognizing-atopic-dermatitis-and-prurigo-nodularis-9891SummaryIn this concise CME/CE podcast, a dermatologist and a primary care clinician discuss atopic dermatitis and prurigo nodularis—two conditions that often present with relentless itch and can significantly affect patients' quality of life. Listen as the two clinicians detail the influence of type 2 inflammation and inflammatory cytokines on the pathophysiology of these diseases, as well as describe their clinical manifestations across skin types. By the end of this podcast episode, listeners will feel much more confident in their ability to identify atopic dermatitis and prurigo nodularis in clinical practice.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Recognize the similarities and differences in the clinical presentations, symptoms, and triggers of AD and PN, including in patients with skin of colorDescribe the role of type 2 inflammation in the pathophysiology of AD and PNThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

In this episode of Speaking of Pets, we sit down with Kathy Deptola from Kathy Deptola Animal Rescue, who shares her invaluable insights into the world of animal rescue and the importance of providing a nurturing environment for our pets. Kathy discusses her creative ways to enrich the lives of her rescue cats, including building climbing structures to keep them active and engaged. We delve into the challenges faced when a beloved pet goes missing, with Kathy offering practical tips for pet owners on how to increase the chances of a safe return. From community outreach to utilizing familiar scents, her advice is a must-listen for any pet parent. Kathy also recounts her inspiring journey into animal rescue, starting from her early volunteer days at a local humane society to establishing her own nonprofit organization. She explains the significance of the adoption process, emphasizing the importance of finding the right home for each animal. Join us as we explore the heartwarming stories of rescued animals, the realities of fostering, and the dedication it takes to ensure their safety and well-being. Plus, we discuss the importance of education in pet ownership and the common misconceptions that can lead to abandoned pets. Whether you're a seasoned pet owner or considering adopting a furry friend, this episode is filled with essential information and heartfelt anecdotes that highlight the joy and responsibility of caring for our pets. Tune in and be inspired to make a difference in the lives of animals in need! --- As a veterinary dermatologist, Dr. Alice Jeromin can tell you that the chronically affected allergic pet condition Atopic Dermatitis is rarely ever 'cured', but can be effectively managed. Command™ Deep Cleansing Shampoo from VetriMax is a top veterinarian-prescribed treatment for skin problems resulting from chronic itch, pyoderma, infection, and allergic dermatitis. VetriMax makes practicing veterinary medicine better by giving doctors high-performing, high-value, evidence-based products. Now with Command Shampoo you can bring that same quality into your regular home routine. Go to Chewy.com and enter promo code COMMAND15 to save 15% off on Command™ Deep Cleansing Shampoo. VetriMax Makes it Better. --- Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. --- All footage is owned by SLA Video Productions.

In this enlightening episode of "Speaking of Pets," we are joined by Bill Bookout, the president, board chair, and founding member of the National Animal Supplement Council (NASC). With a wealth of knowledge in the animal supplement industry, Bill serves as a critical voice in ensuring the safety and efficacy of products designed for our beloved pets, including dogs, cats, and horses. Bill explains the vital role of the NASC in evaluating animal supplements, emphasizing that the FDA does not review these products. He outlines the rigorous standards the council upholds to ensure that pet owners can trust the supplements they choose for their furry friends. From clarifying the definitions of dietary supplements to discussing the importance of quality raw materials, Bill provides invaluable insights for pet owners navigating the myriad of supplement options available. Throughout the episode, we dive into the complexities of the industry, including the implications of sourcing ingredients globally, the significance of good manufacturing practices, and the heightened scrutiny surrounding hemp and CBD products. Bill shares his personal journey into the world of animal health and nutrition, fueled by his love for animals and a desire to make a difference. Join us as we discuss what pet owners should look for when purchasing supplements, the red flags to watch out for, and the importance of supporting responsible companies. This episode is a must-listen for anyone who wants to ensure their pets receive the best care possible! --- As a veterinary dermatologist, Dr. Alice Jeromin can tell you that the chronically affected allergic pet condition Atopic Dermatitis is rarely ever 'cured', but can be effectively managed. Command™ Deep Cleansing Shampoo from VetriMax is a top veterinarian-prescribed treatment for skin problems resulting from chronic itch, pyoderma, infection, and allergic dermatitis. VetriMax makes practicing veterinary medicine better by giving doctors high-performing, high-value, evidence-based products. Now with Command Shampoo you can bring that same quality into your regular home routine. Go to Chewy.com and enter promo code COMMAND15 to save 15% off on Command™ Deep Cleansing Shampoo. VetriMax Makes it Better. --- Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. --- All footage is owned by SLA Video Productions.

In this episode of our podcast, we're thrilled to dive into the fascinating world of canine intelligence with New York Times bestselling author Jennifer Holland, who joins us to discuss her latest book, *Dog Smart: Life-Changing Lessons in Canine Intelligence*. Hosts Alice and Janet reminisce about their own experiences with dogs and share their admiration for Jennifer's adventurous spirit, which includes everything from scuba diving with tiger sharks to camping in New Guinea. They explore the incredible intelligence of dogs, revealing how this book opened their eyes to the depth of canine cognition and the unique ways dogs communicate and adapt. Jennifer shares her journey into writing this book, detailing her experiences training with Seeing Eye dogs and the profound lessons learned about trust and intelligent disobedience. The conversation flows into the remarkable abilities of dogs, from detecting medical conditions to their roles in search and rescue missions. Prepare for an engaging discussion filled with heartwarming stories, surprising insights, and a newfound appreciation for our furry companions. Whether you're a dog owner, animal lover, or just curious about the intelligence of dogs, this episode is sure to inspire and educate. Tune in for a compelling exploration of the bond between humans and dogs and the lessons they teach us every day! https://www.jenniferhollandwriter.com/ --- As a veterinary dermatologist, Dr. Alice Jeromin can tell you that the chronically affected allergic pet condition Atopic Dermatitis is rarely ever 'cured', but can be effectively managed. Command™ Deep Cleansing Shampoo from VetriMax is a top veterinarian-prescribed treatment for skin problems resulting from chronic itch, pyoderma, infection, and allergic dermatitis. VetriMax makes practicing veterinary medicine better by giving doctors high-performing, high-value, evidence-based products. Now with Command Shampoo you can bring that same quality into your regular home routine. Go to Chewy.com and enter promo code COMMAND15 to save 15% off on Command™ Deep Cleansing Shampoo. VetriMax Makes it Better. --- Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. --- All footage is owned by SLA Video Productions.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes E. James Song, MD, Chief Medical Officer at Frontier Dermatology, to explore the nuances of systemic therapy selection for atopic dermatitis (AD) and offer practical guidance on tailoring treatment plans to optimize outcomes for these patients. They begin by discussing the importance of considering patient-specific factors, such as contraindications, access, and age, when selecting among the 3 currently available biologics for AD: dupilumab, tralokinumab, and lebrikizumab. While these therapies share many similarities, nuanced differences—such as dupilumab's approval for younger patients and asthma comorbidity, or lebrikizumab's sustained efficacy after discontinuation—can guide treatment decisions. They also discuss adverse events, including conjunctivitis and dupilumab-associated facial erythema, highlighting strategies for managing these issues. Dr Song notes that switching within the IL-13 pathway can often resolve conjunctivitis and speculates on the possible mechanisms behind facial redness. They then explore one critical insight: the potential for patients to fail one biologic and still respond to another within the same class. While complete nonresponders may benefit from switching to a different class, such as JAK inhibitors, partial responders often do well with another IL-13 inhibitor. Tune in to the full episode to explore more insights on optimizing AD management, including how to navigate biologic options, manage adverse events, and approach challenging cases while embracing new therapies and tailoring care to each patient's unique needs.

On this episode, we evaluate the current guidelines and evidence-based treatment strategies for managing atopic dermatitis. We compare and contrast the efficacy, safety profiles, and appropriate use of various therapies. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Letosky's watch. Tune in for a deep dive into the world of K9 rehabilitation and discover how we can better support our beloved pets! Dr. Letosky is a general practitioner at the Avon Lake Animal Clinic, and has been a part of the team since 1996. She has special interests in ultrasonography, and obtained her certification in this field through the University of Illinois Executive Veterinary Program. Dr. Letosky is also a Certified Canine Rehabilitation Practitioner. She received this certification through the University of Tennessee. She earned her Bachelors of Science from Wayne State University and her Doctorate of Veterinary Medicine from Ross University School of Veterinary Medicine. In addition to practicing veterinary medicine, Dr. Letosky also enjoys golfing and birding. Her love for animals extends to her home life, where she has three pets: two cats named Radar and Shade, and a Boston Terrier named Tug. In 2022 Dr. Letosky was awarded a certificate in Veterinary acupuncture (CVAT) through the Canine Rehab Institute. --- As a veterinary dermatologist, Dr. Alice Jeromin can tell you that the chronically affected allergic pet condition Atopic Dermatitis is rarely ever 'cured', but can be effectively managed. Command™ Deep Cleansing Shampoo from VetriMax is a top veterinarian-prescribed treatment for skin problems resulting from chronic itch, pyoderma, infection, and allergic dermatitis. VetriMax makes practicing veterinary medicine better by giving doctors high-performing, high-value, evidence-based products. Now with Command Shampoo you can bring that same quality into your regular home routine. Go to Chewy.com and enter promo code COMMAND15 to save 15% off on Command™ Deep Cleansing Shampoo. VetriMax Makes it Better. --- Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. --- All footage is owned by SLA Video Productions.

Sponsored by Elanco. Unlike conventional treatments for canine allergic and atopic dermatitis, novel targeted therapies provide rapid relief with a reduced risk for adverse events. In this podcast, Andrew Rosenberg, DVM, and Adam Christman, DVM, MBA, react to the availability of a once-daily oral JAK inhibitor, highlighting it as a significant advancement in managing difficult skin conditions in dogs. Learning Objectives: Understand the various causes of canine allergic and atopic dermatitis. Gain insight into using available treatment options to manage canine allergic and atopic dermatitis. Learn how Zenrelia™ (ilunocitinib tablets) can be used to offer dogs relief from pruritus associated with allergic and atopic dermatitis.  DISCLAIMER Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1649 INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFETY INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

Looking for an integrative approach to infant AD? We've got just the expert. This week, we're joined by Dr. Samantha Casselman as she helps us navigate how to work with concerned parents to improve their child's eczema. Listen in as she discusses the nuances of steroid phobia, how to create an eczema action plan, and how to best communicate with parents. Samantha Casselman, DNP CPNP-PC is a Pediatric Nurse Practitioner in Phoenix, AZ. She is practice owner of Happy Skin Pediatric Dermatology, where she specializes in infant and child atopic dermatitis. She is affiliated with the National Eczema Association and current executive board member of the National Association of Pediatric Nurse Practitioners.   This episode concludes Season 6. Thank you for tuning in! Season 7 begins March 13, 2025. For access to CE/CME courses year-round, become a member at LearnSkin.com.

A troubling disconnect between medical expertise and insurance mandates is putting patients' health at risk. Policies like step therapy and prior authorization are forcing individuals into treatments not recommended by their doctors—often with devastating consequences. In this episode, we hear from a patient who endured months of suffering due to her insurer's 'fail-first' requirements. We also talk with a doctor navigating this impossible system and a biotech leader fighting to ensure innovative treatments reach the patients who need them most. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

On this episode Lara and Vyanka talk to Prof Alan Irvine from St James's Hospital in Dublin all about the immunology of atopic dermatitis and eczema. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, invites Peter Lio, MD, a clinical professor of dermatology at Northwestern University, to explore the complexities of selecting therapies for atopic dermatitis (AD) with a particular focus on the newly approved IL-13 inhibitor, lebrikizumab. With a growing number of treatment options, Dr Lio and Dr Del Rosso examine how these therapies are enhancing patient management in unique ways. The discussion opens with a look at the current "embarrassment of riches" in AD treatments. Dermatologists now have multiple biologic options to choose from, each with distinct features. Dr Lio highlights lebrikizumab's flexible dosing, which can shift to once monthly after the initial treatment period, potentially offering patients a more manageable treatment routine. They also explore key differences among IL-13 inhibitors, such as lebrikizumab's unique binding characteristics that may influence the overall balance of IL-13 in the body. Dr Lio also notes the possibility of achieving relative remission for certain patients on lebrikizumab, as suggested by a long-term extension study where some patients maintained improvement even after stopping the drug. They also cover the safety and tolerability aspects of AD therapies, including conjunctivitis, arthropathy, and erythematous reactions sometimes seen with these drugs. Dr Lio shares insights on managing these side effects, emphasizing that despite similar mechanisms of action, switching between IL-13 inhibitors may alleviate adverse reactions for certain patients. Tune in to the full episode for expert insights on differentiating and integrating the latest therapies for AD, strategies for engaging patients in their treatment plans, and valuable guidance on navigating today's expanding therapeutic landscape.

This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics: Challenges in achieving treatment targets in AD Therapeutic inertia and clinical implications of inadequate response Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Atopic Dermatitis (Eczema)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Dermatology section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠ Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

In today's VETgirl online veterinary CE podcast, we talk to Dr. Darren J Berger, DACVD on all things Canine Atopic Dermatitis (CAD). In veterinary medicine, we see atopy a ton, but we still see a lot of “failure” in treatment! Tune in to learn what we can do to better treat CAD, how to prevent our pet owners from getting so frustrated by it, and when to refer these cases to a dermatologist! Learn what your ultimate goal is in treating pruritic dogs, and what's the latest innovation in treating dogs with CAD!Sponsored By: Elanco

Hair loss can have many root causes for both men and women, but there are solutions! On this episode of Vitality Radio, Jared talks to Rosalynde Marchant from Hairs a Million about the products she developed post-chemo treatments to regrow her own hair. She's since been having incredible success sharing her products with people who are losing hair for a variety of reasons. Jared and Roz discuss how topical nutrients can regrow hair, but also how to deliver the body what it needs internally to ensure it has the nourishment it needs to grow healthy hair. Products:Hairsamillion Ridgecrest Herbals Hair ReViveAdditional Information:Code: haircombo - $10 off when you purchase the Hairs a Million serum along with Hair ReViveVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Mona Shahriari, MD, associate director of clinical trials at Central CT Dermatology and assistant clinical professor at Yale University, to discuss the recent FDA approval of lebrikizumab, approved for atopic dermatitis (AD) in patients 12 years of age and up who have failed topical treatments like corticosteroids or calcineurin inhibitors, and its potential impact on treatment strategies. They begin by explaining the drug's flexibility, with an initial loading dose followed by maintenance dosing that can be extended to once a month for patients who achieve a satisfactory response after 16 weeks. Dr Shahriari emphasizes that determining an adequate response involves more than skin clearance; persistent symptoms like itchiness can indicate the need to continue more frequent dosing. They then discuss how many patients maintained their treatment response even after tapering dosing, with some experiencing benefits through week 52, suggesting a durable effect even when the treatment was paused. When discussing real-world use, Dr Shahriari notes lebrikizumab's convenience for both patients and providers, as it does not require baseline or ongoing lab monitoring and has no drug-drug interactions. Addressing safety, Dr. Shahriari notes that while common side effects like conjunctivitis and injection site reactions were observed, the drug was generally well-tolerated without any major safety concerns. They conclude by reflecting on the heterogeneity of AD, noting that patients may respond differently to medications even within the same class and that it's important to have multiple options to personalize treatment for each patient. Tune in to the full episode to hear more about lebrikizumab's clinical performance and the growing toolbox for AD management that is allowing dermatologists to offer safer, more targeted treatments that greatly improve patients' quality of life.

In episode eight of Getting to Know Your Research, Dr. Wenelia Baghoomian discusses her 2021 PeDRA Research Fellowship project titled The Impact of Topical Prescription Drug Delivery Devices in the Adherence and Ease of Use of Corticosteroids in Pediatric Patients with Atopic Dermatitis. Listen to learn about the inspiration for this project and the partnerships that made it successful.

Atopic dermatitis is the single most common chronic condition in the world, but it's also the most misunderstood and mistreated. People who struggle with it endure years of discomfort, a drop in their quality of life, a revolving door of doctors, reams of blood tests and a multitude of treatments. These treatments often focus on food and finding out what they can stop eating to get better. Though this is well-intentioned advice, it is misguided. The food you eat isn't the root cause of eczema. Growing data show that eczema is what causes food allergies. This changes everything about how eczema is treated, and also how to prevent it in infants. For high-risk babies, early and frequent exposure to food can significantly reduce the chance of atopic dermatitis and potentially set them up for an allergy-free life. In this episode, I'm joined by the Chief Medical Officer at Snö Asthma & Allergy, Dr. Stuart Carr. He shares the truth about atopic dermatitis, and why there are more treatment options on the table other than avoiding certain foods and hoping for the best.  Things You'll Learn In This Episode  -Sensitization vs. true allergy  Food sensitivity and allergy are two very different things that often get mixed up. How do doctors determine if you're allergic to something? -The right way to restrict your diet  Many people use elimination diets to try and combat allergies. How do you do this without actually increasing your chance of allergy? -Early and often exposure is key Parents of infants prone to eczema often delay the introduction of certain foods, could this actually make the likelihood of allergy higher? -Food in mouth, but not on skin Atopic dermatitis patients think eating certain foods will trigger a reaction. What actually triggers a reaction?  Guest Bio Dr. Carr has been Chief Medical Officer at Snö Asthma & Allergy in Abu Dhabi since January 2019, having spent the previous 20 years in academic clinical allergy practice in Edmonton, Canada.  He was an Associate Clinical Professor at the University of Alberta, and is also a Past-President of the Canadian Society of Allergy and Clinical Immunology, and a reviewer for Allergy, Asthma & Clinical Immunology, the journal of the CSACI. His primary interests are pediatric asthma, food allergy, and eosinophilic esophagitis, and Dr. Carr is currently involved in a Canada-wide collaboration examining the safety and effectiveness of oral immunotherapy for peanut and other food allergies in preschool children. To learn more follow @allergydoc4kidz on Instagram   About Your Host Hosted by Dr. Deepa Grandon, MD MBA, triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidenced-based lifestyle medicine.   ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced. Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm so our show reaches more people. Thank you!

Seeking an effective remedy for chronic eczema? This company offers a 60-day full refund if their anti-itch spray doesn't provide the relief you're looking for! Find more information at https://cleered.net Cleer Products LLC City: White Plains Address: 75 South Broadway Website: https://cleered.net Email: Info@cleerproducts.net

Are you curious about how biologic medications are transforming the treatment of asthma, eczema, allergies, and more? Dr. Perdita Permaul joins Dr. Gupta and Kortney to discuss the available biologic medications for allergic conditions. We walk through the eight biologics currently available for allergic diseases, explaining how these medications target different parts of the immune system to treat allergic conditions more effectively than traditional medications. Dr. Permaul explains how biologics have evolved since 2003 and how they are changing the way allergic conditions are treated. She also explains why some of the biologics treat multiple diseases, whereas some are only approved for one.  What we cover in our episode about the available biologics for allergic conditions How biologics work for allergic conditions: We unpack how biologic medications target specific parts of the immune system, reducing inflammation and improving the quality of life for patients with allergic diseases. History and evolution of biologics: Dr. Permaul walks us through the timeline of biologics, starting with Xolair in 2003 and how these treatments have expanded to target other conditions over time. Which biologics treat which conditions: From asthma and eczema to food allergies and nasal polyps, we break down which biologics are available and how they help patients with allergic conditions. Future of biologics: Dr. Permaul discusses the potential of biologics to be used for more conditions in the future, including ongoing research into food allergy treatments. Biologics Cheat Sheet Below is a list of the 8 biologics discussed in this episode. We have briefly outlined their mechanism of action along with the approved conditions and ages the drug is available for presecription.  Omalizumab (Xolair) Xolair works by binding to IgE to prevent allergic reactions. It has since been approved for chronic hives, nasal polyps, and food allergies. Allergic asthma: 6+ Chronic idiopathic urticaria (hives: 12+ Chronic rhinosinusitis with nasal polyps (CRSwNP): 18+ Food allergies:1+ Mepolizumab (Nucala) Targets and blocks interleukin-5 (IL-5) play a key role in the activation and priming of eosinophils, a type of white blood cell that causes inflammation in asthma. Eosinophilic Asthma: 6+ CRSwNP: 18+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Hypereosinophilic Syndrome: ≥6 months Reslizumab (Cinqair) Targets and blocks interleukin-5 (IL-5). Eosinophilic asthma: 18+ Benralizumab (Fasenra) Binds to the IL-5 receptor, preventing eosinophils from growing and causing inflammation. Eosinophilic asthma: 6+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Dupilumab (Dupixent) Targets and blocks IL-4 and IL-13 to reduce inflammation Asthma: 6+ Atopic Dermatitis: 6 months+ CRSwNP: 18+ Eosinophilic Esophagitis (EoE): 1+ (> 33 lbs) Approved for prurigo nodularis (PN): 18+ Tezepelumab (Tezspire) Blocks thymic stromal lymphopoietin (TSLP). Asthma: 12+ Tralokinumab (Adbry, Adtralza) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ Lebrikizumab (Ebglyss) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ (> 40 lbs) ________ This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Sanofi-Regeneron for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement. Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/

Interview with Maria Teresa García-Romero, MD, MPH, author of Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Hosted by Adewole S. Adamson, MD. Related Content: Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis

Interview with Maria Teresa García-Romero, MD, MPH, author of Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Hosted by Adewole S. Adamson, MD. Related Content: Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis

The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis

Nemolizumab, pruritis, and Dr. Shawn Kwatra! - Food and atopic dermatitis - Dermasphere clip show: episodes 131-140! Find Dr. Shawn Kwatra on social media at DrShawnKwatra Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: www.youtube.com/@dermaspherepodcast and VuMedi!: www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare - ⁠ Connect with us! - Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!

This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: The pros and cons of steroid use in treating AD Targeted non-steroidal topical therapies approved by the FDA Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals Recommendations for long-term symptom control in AD patients

In this episode of Derms and Conditions, host James Del Rosso, DO, speaks with Mark Lebwohl, MD, Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai, about the role of Janus kinase (JAK) inhibitors, particularly upadacitinib, in treating atopic dermatitis. They provide insights into the benefits of JAK inhibitors compared to monoclonal antibodies, patient selection, and the implications of recent clinical data. They begin by explaining that while monoclonal antibodies like dupilumab and tralokinumab have been effective for many patients, JAK inhibitors can offer a powerful alternative for those seeking better control of their symptoms. They emphasize the importance of regularly assessing patient satisfaction with their treatment and exploring whether a switch to a JAK inhibitor might be beneficial. Dr Lebwohl then refers to treat-to-target principles recently established by a consensus conference, where EASI 75 is a moderate goal and EASI 90 is optimal. JAK inhibitors, he suggests, are more likely to help patients reach these higher targets, especially when symptoms persist despite achieving EASI 75. They continue to discuss data demonstrating that upadacitinib significantly improves outcomes, with 40.8% of patients achieving EASI 90 compared to 22.5% with dupilumab. Additionally, upadacitinib-treated patients are more likely to report minimal impact on their quality of life as measured by the Dermatology Life Quality Index. Finally, Dr Lebwohl stresses the importance of discussing the risks associated with JAK inhibitors, including boxed warnings, in a clear and contextualized manner to help patients make informed decisions. Tune in to the full episode to gain a deeper understanding of the nuances of JAK inhibitors in AD treatment, including practical tips for patient management, insights into the latest clinical data, and optimizing patient care.

This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics: Mechanistic differences between JAKi and biologics for treatment of AD Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics Pearls for prescribing JAKi to AD patients Strategies for choosing JAKi vs biologics based on safety and patient factors

Peds derm discussions with Dr. Lisa Swanson! - Infant gut microbiota and risk for allergic disease - Maternal vitamin D and atopic dermatitis - Tocilizumab for H syndrome - Nadolol = or > propranolol for hemangiomas Lisa Swanson can be found at lisaswansonmd@gmail.com Want to donate to the cause? Do so here!Donate to the podcast: uofuhealth.org/dermasphereCheck out our video content on YouTube:www.youtube.com/@dermaspherepodcastand VuMedi!: www.vumedi.com/channel/dermasphere/The University of Utah's DermatologyECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -⁠ Connect with us!- Web: ⁠dermaspherepodcast.com/⁠ - X: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle's other podcast,SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠Dermasphere has received an unrestricted educational grant from Incyte Corporation. Thanks, Incyte!Check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learnmore dermatology!

PayerTalkCE Presents: Tackling the Clinical, Economic, and Humanistic Burden of Atopic Dermatitis On this award-winning episode hosted by Dr. Steven Kheloussi (Highmark, Inc.) and featuring guest Ashley Ellis (National Eczema Association), the dialogue revolves around the multifaceted challenges presented by atopic dermatitis. Ashley shares her personal journey as a mother of a child with atopic dermatitis, providing insights into the patient and caregiver experience. The discussion covers the clinical management of the condition, its economic implications for families, and the broader humanistic impact on patients' lives, emphasizing the need for empathy and understanding in healthcare interactions. The conversation also touches on the importance of effective patient-provider communication, the potential benefits of newer treatment options, and the complexities involved in navigating health insurance systems to access necessary care. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

If you're suffering from atopic dermatitis, the condition isn't just skin deep. Every itch can cascade into a world of discomfort and pain. Every flare up is an interruption to your quality of life, and every scar can leave you feeling less confident. This is a reality millions live in, and often it leads to anxiety and depression, which can exacerbate the skin irritation further.   That's why the condition has to be treated holistically. It's not just about dealing with itchy and inflamed skin. It's about addressing all the ways it affects someone's entire life.   The good news is, we're living in the golden age of atopic dermatitis therapies, and people can get what they need to manage the condition and put it into remission. What causes atopic dermatitis? How can we use lifestyle factors to manage it better?   Why is it critical for physicians to understand the different manifestations of skin conditions in different skin colors? In this episode, I'm joined by board-certified dermatologist and founder of Above & Beyond Dermatology, Dr. Stephen Lewellis. We talk about how to improve your quality of life if you're dealing with atopic dermatitis, and all the interventions and solutions that are available.   If you have a higher risk of atopic dermatitis, stress, irritants and changes in weather are all factors that raise the score of it expressing on your skin. If we can lower the morbidity threshold, that can manage the condition.  -Dr. Stephen Lewellis    Three Things You'll Learn In This Episode   -The root cause of atopic dermatitis Atopic dermatitis is the most common skin disease in the world. What makes someone more prone to it and what triggers flare ups?   -Remission not cure In oncology, we talk about getting cancer into remission. Could changing our language on atopic dermatitis to management serve people better than talking about a cure?    -Don't sound like a textbook Physicians have to get better at talking about atopic dermatitis so that they educate patients and provide solutions.   Guest Bio   Dr. Stephen Lewellis is a board-certified dermatologist and founder of Above & Beyond Dermatology, an integrative dermatology practice that runs on trust, transparency, accountability, and good old fashioned hospitality. Dr. Stephen Lewellis also hosts The Direct Care Derm podcast and writes the Above & Beyond Dermatology newsletter. For more information, head to https://lewellismd.com/ or connect with Dr. Lewellis on LinkedIn.

PayerTalkCE Presents: Interpreting A Complex Puzzle: US Commercial Payer Coverage of Atopic Dermatitis (AD) Treatments Varies Widely On this episode Dr. Steve Kheloussi (Highmark) engages in a fascinating discussion with Dr. James Chambers (Tufts Medical Center). They explore the intricate world of commercial health plans' coverage decisions for atopic dermatitis treatments in the US. Dr. Chambers provides insights from his extensive research into how various payers are navigating the rapidly evolving treatment landscape for AD, particularly with the advent of specialty therapies like biologics. This conversation sheds light on the significant variability in coverage policies, the evolution of these policies over time, and the impact on patient access to critical treatments. Health plan professionals will gain a deeper understanding of the challenges and considerations in formulating coverage policies for AD treatments, emphasizing the need for evidence-based decision-making and the potential implications for patient care and outcomes. This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/atopicdermtreatments/. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen